Given that most cannabinoids, including delta-9 tetrahydrocannabinol (Δ9-THC), CP55,940, and WIN55,212–2, are mixed agonist acting at both the cannabinoid type-1 (CB1) and type-2 (CB2) receptors, we assessed whether pretreatment with the selective CB1 antagonist rimonabant, the selective CB2 antagonist SR144528, or the opioid antagonist naloxone could prevent decursinol-induced anti-allodynia in a model of neuropathic pain. Here, CNR2 is linked to neuropathic pain.